the Republic of Moldova will add vaccination against human papillomavirus (HPV) to the routine immunization schedule

Moldova (Republic Of)
NITAGs
6 February 2017

Vaccination against human papillomavirus (HPV) will be added to the routine immunization schedule in the Republic of Moldova in November 2017. Timely vaccination against HPV prevents infection with viruses that are the leading cause of cervical and other cancers. The Ministry of Health’s decision to introduce the vaccine followed the recommendation of the country’s independent national immunization technical advisory committee (NITAG) based on its thorough review of available evidence. 

Flag_of_Moldova.svg.png

WHO/Europe support for the decision-making process has included organization of a national conference and stakeholders’ meeting on HPV disease and vaccines on 29–30 September 2016 in Chisinau, Republic of Moldova. The conference brought together public health professionals and clinicians (obstetricians/gynaecologists, paediatricians, oncologists), medical academia, Ministry of Health officials, representatives of the Medical and Pharmaceutical State University, the national immunization programme, United Nations agencies and other stakeholders. They discussed the burden of cervical cancer in the Republic of Moldova and the experience of countries globally and in the European Region in implementing the HPV vaccine, including country efforts to address vaccine safety concerns, as well as other challenges and lessons learnt.

Burden of HPV-related disease

HPV poses a serious burden on public health in the Republic of Moldova. According to WHO estimates, HPV caused cervical cancer in more than 470 women and was responsible for 210 deaths in the country in 2012 alone. Cervical cancer is the third most prevalent of all cancers among women. The Republic of Moldova is among the top 5 countries in the WHO European Region with the highest cervical cancer mortality rates. The introduction of HPV vaccine along with implementation of other preventive interventions will help significantly reduce morbidity and mortality owing to cervical cancer and other HPV-related conditions.
By 2016, 28 countries of the WHO European Region and 67 countries globally introduced HPV vaccine into routine immunization programmes; and after 10 years and more than 200 million doses used, there is strong evidence to support that HPV vaccine is effective and safe. The successful introduction of HPV vaccine requires implementation of intensified public awareness activities and active involvement of health workers.

Related News & Events

  • Côte d’Ivoire
    NITAGs

    ESTABLISHMENT AND STRENGTHENING OF NITAG IN IVORY COAST: SUCCESS AND CHALLENGES

    26.04.2017

    The NITAG session at the April SAGE meeting 2017 includes presentations of three committees: JCVI (UK NITAG), Sri Lanka and Senegal. The NITAG of Cote d'Ivoire is taking this opportunity to present its success and challenges.

    Read more
  • NITAGs

    Get ready for the next GNN meeting and read the 2016 report

    21.04.2017

    The Global NITAG Network will meet in June 28th - 29th, 2017 in Berlin. The Organizing Committee composed of representatives of the Robert Koch Institute (as the hosting institutions), AMP-HPID, US CDC, WHO and representatives from the NITAG network are currently developing the meeting agenda. Last year report can be downloaded to get prepared for this year meeting and get familiarized with the NITAG members. 

    Read more
  • Costa Rica
    NITAGs

    Voice from the field: Roberto Arroba

    10.04.2017

    Roberto Arroba is the National coordinator of immunization in Costa Rica, in charge of the secretariat of the NITAG and also a core group member of the Global NITAG Network (GNN).

    Read more